Health Care

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts

Amazon Overhauls Healthcare Business To Streamline Structure As Exec Officers Leave

Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts

Amazon Overhauls Healthcare Business To Streamline Structure As Exec Officers Leave

Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499

T. Rowe Price Expands ETF Lineup With 3 Actively Managed Sector Picks Across Key Sectors

Health Care Recent News

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst

Intuitive Surgical remains in focus as analysts weigh reprocessing risks after Restore Robotics secures FDA clearance for remanufactured tools.

Trump's Tax Plan Could Leave Millions Uninsured, Hit Rural America Hard

Trump's proposed tax and spending bill could slash $785 billion from Medicaid, threatening rural hospitals and potentially leaving 11 million more Americans uninsured.

FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.

Medtronic Is Separating Its Diabetes Business - Good News For Investors

AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion

AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.

FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up

The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine.

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.

Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt

Simulations Plus stock fell after it issued a weaker 2025 outlook and forecast Q3 revenue below expectations, citing biotech market pressures.